PasitheaLogo.png
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
13 févr. 2024 07h59 HE | Pasithea
Pasithea Tx activates four U.S. sites for Phase 1 Trial of its next-gen MEK inhibitor, aiming to assess safety, efficacy, and biomarker data.
VIR_logo_large_color.jpg
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
03 oct. 2023 07h59 HE | Vir Biotechnology, Inc.
Vir Biotechnology Awarded approximately $50 million in BARDA Funding to Support Development of Antibody Platform Technologies for COVID-19
VIR_logo_large_color.jpg
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
20 sept. 2023 08h00 HE | Vir Biotechnology, Inc.
– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine – – Phase 1 trial supported by the Bill & Melinda Gates Foundation,...
Atlantic Healthcare Reports Results from Phase 1 Trial of Tablet for Crohns
27 sept. 2018 08h00 HE | Atlantic Healthcare plc
CAMBRIDGE, UK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Oral Alicaforsen Appears Safe and Well-Tolerated via NEWMEDIAWIRE – Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a specialist...